Nammalwar Sriranganathan

Title: Nammalwar Sriranganathan: Innovator in Vaccine Development

Introduction

Nammalwar Sriranganathan is a notable inventor based in Blacksburg, VA (US). He has made significant contributions to the field of vaccine development, particularly in the prevention and treatment of Brucellosis. With a total of 2 patents, his work has garnered attention in the scientific community.

Latest Patents

Sriranganathan's latest patents include the development of a live, attenuated, recombinant vaccine for Brucellosis. This innovative vaccine utilizes a recombinant, attenuated strain with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity. This approach aims to prevent or treat Brucellosis effectively. Additionally, he has developed live Brucella vaccines and methods for preparing these vaccines, which are protective against Brucellosis. These vaccines are created by introducing a deletion in the rfbU gene of a Brucella strain, resulting in attenuation while maintaining the necessary immunogenicity to elicit a protective immune response.

Career Highlights

Throughout his career, Sriranganathan has worked with esteemed organizations, including the US Government as represented by the Secretary of the Army and Virginia Tech Intellectual Properties, Inc. His expertise in vaccine development has positioned him as a key figure in the field.

Collaborations

Sriranganathan has collaborated with notable colleagues such as Gerhardt G Schurig and Stephen M Boyle. These partnerships have contributed to the advancement of his research and innovations.

Conclusion

Nammalwar Sriranganathan's work in vaccine development, particularly for Brucellosis, showcases his dedication to advancing medical science. His patents and collaborations reflect his significant impact in the field.